ARA-290 (Cibinetide, Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser) is a synthetic 11-mer peptide engineered from the helix-B surface domain of erythropoietin, developed to selectively activate the Innate Repair Receptor (a heterodimer of EPOR and CD131) without triggering EPO’s effect on red blood cell production. At a molecular weight of approximately 1257.4 g/mol, it is structurally distinct from full-length EPO and acts through a separate, tissue-protective signaling pathway.
Research has examined ARA-290 in two human trials in sarcoidosis-associated small fiber neuropathy, plus mechanism studies in inflammation and wound-healing models, with attention to its effects on corneal nerve fiber density and inflammatory signaling through CD131/JAK2 and NF-kB p65 inhibition.
Each Etched Research vial contains 10mg of lyophilized powder.
Specifications:
– Molecular Formula: C55H82N18O18
– Molecular Weight: ~1257.4 g/mol
– Sequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
– CAS Number: 1208243-50-8
– PubChem CID: 91810664
– InChIKey: WZTIQQBMSJTRBR-WYKNNRPVSA-N
– Form: Lyophilized powder
– Storage: -20°C (lyophilized); 4°C once reconstituted, use within 30 days
FOR IN VITRO RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION, INGESTION, OR ANY IN VIVO USE.
- What it is: A peptide engineered from erythropoietin, built to activate a tissue-protective signaling pathway without EPO’s effect on red blood cells.
- Researchers have studied it for: sarcoidosis-associated small fiber neuropathy, in two human trials, plus mechanism work in inflammation and wound-healing research models.
- Evidence level: Real human trial data exists, in one specific rare-disease population. The company that ran those trials, Araim Pharmaceuticals, has since ceased operations, and no Phase III trial was ever completed.
- The short version: ARA-290 has real, published human trial data behind it, which is genuinely uncommon in this category. That data is narrow, one disease population, one structural endpoint, and a development program that stopped before full approval. This is a research summary, not a reason to use anything.




